翰森製藥(03692.HK)獲普米斯HS-20117全球獨家許可
翰森製藥(03692.HK)公布,與普米斯生物技術(珠海)訂立許可協議。據此,公司獲得獨家許可,以於全球範圍內將HS-20117用於雙特異性抗體偶聯物產品開發、生產、商業化,並有權進一步分許可。HS-20117為通過特異性靶向腫瘤抗原EGFR和cMet抑制腫瘤生長和存活,目前正處於I期臨床研究階段。
公司將支付首付款和基於ADC產品的開發、註冊及基於銷售的商業化里程碑潛在付款合共不超過50億人民幣,並支付基於全球淨銷售額的分級特許權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.